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Toshiyuki Habu and Jiyeong Kim
Abstract
Posttranslational protein modifications by mono- or polyubiquitination are
involved in diverse cellular signaling pathways and tightly regulated to ensure
proper function of cellular processes. Three types of enzymes, namely ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-
protein ligases (E3), contribute to ubiquitination. Combinations of E2 and E3
enzymes determine  the fate of their substrates via ubiquitination. The seven
lysine residues of ubiquitin, Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63,
can serve as attachment sites for other ubiquitin molecules. Lys48 (K48)-linked
polyubiquitination facilitates recognition of the conjugated protein by proteasome
molecules and subsequent proteolytic degradation of the target protein. By contrast,
Lys63 (K63)-linked polyubiquitination appears to be involved in polyubiquitin
signaling in critical cellular processes, such as DNA repair, regulation of the I-
kappaB kinase/NF-kappaB cascade, or T cell receptor signaling, but not protein
degradation. In this review, we describe the properties of ubiquitin modification
enzymes and the structural interplay among these proteins.
Keywords: E1 ubiquitin, ubiqutin-activating enzyme, E2 ubiquitin-conjugating
enzyme, E3 ubiquitin ligase
1. Introduction
Very large-scale studies of protein ubiquitination have been conducted over the
past two decades. Ubiquitin modification is mediated by three types of enzyme
activity, mediated out by E1 ubiquitin-activating enzymes (UBA; also referred to as
UAE or E1 enzymes; EC 6.2.1.45), E2 ubiquitin-conjugating enzymes (UBC; also
termed E2 ubiquitin-carrier proteins or E2 enzymes; EC 2.3.2.23), and ubiquitin-
protein ligases (E3 enzymes). To better understand the molecular mechanisms
underlying ubiquitin modification, this review focuses on the structural interactions
between ubiquitin modification enzymes and their functions.
2. Types of ubiquitin and ubiquitin-like proteins (UBLs)
Ubiquitin is a small, highly conserved 76 amino acids polypeptide found through-
out eukaryotic cells, that modifies cellular proteins. Two mammalian ubiquitin genes,
UBB and UBC, encode polyubiquitin and another two genes, RPS27A and UBA52
encode ubiquitins fused with ribosomal proteins [1]. Ubiquitin is produced as pre-
cursor peptides that are proteolytically processed by deubiquitinating enzymes into
active forms with C-terminal glycine residues. The C-terminal glycine (Gly76) and
seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) of
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ubiquitin are essential for ubiquitin modification. There is 96% sequence identity
between human and yeast ubiquitin, and the two glycine and seven lysine residues
are conserved throughout the eukaryotic kingdom.
Ubiquitin-like proteins (UBLs) do not share sequence homology with ubiquitin
but also function as protein modifiers. A number of UBLs have been reported,
including SUMO1/SMT3, SUMO2–4 [2–4], Neural-precursor-cell-expressed devel-
opmentally downregulated protein-8 (NEDD8)/RUB1 [3, 5, 6], ISG15 [6, 7], ATG8/
APG8 [8], ATG12/APG12 [9], URM1 [3], and homologous to ubiquitin 1 (HUB1)
[10]. During protein modification by ubiquitin and UBLs, specific activating, con-
jugating, and ligase enzymes, catalyze attachment of the modifier to target proteins.
Similar to ubiquitin, UBLs are also produced as precursors, and deubiquitinating
enzymes expose their C-terminal glycine residues to activate them, although HUB1
lacks a C-terminal diglycine sequence.
The SUMO-1 protein has only 18% sequence identity with ubiquitin, but con-
tains the ββαββαβ fold structure characteristic of the ubiquitin protein family [2].
The hydrophobic cores of SUMO-1 and ubiquitin are similar; however, the overall
charge surface topology of SUMO-1 differs significantly from that of ubiquitin or
other UBLs [2, 11]. The selective modifications mediated by the four SUMO homo-
logs, SUMO-1, SUMO-2, SUMO-3, and SUMO-4 [12–16], remain to be determined.
In addition, SUMO has an N-terminal extension (approximately 20 amino acids)
not present in ubiquitin, which is required for SUMO function [17]. A consensus
motif and lysine residues involved in SUMOylation are present in SUMO-2, SUMO-
3, and SUMO-4 and well-conserved; however, these SUMO proteins do not have
Lys residue counterparts of ubiquitin Lys 48 and 63.
NEDD8 shows 58% sequence identity and 80% sequence similarity to ubiquitin
polypeptide. By contrast, the ATG12 sequence is unrelated to that of ubiquitin, and
forms a covalent protein complex with ATG5, which is required for autophagy; this
reaction requires the C-terminal glycine residue of ATG12 and a lysine residue in
ATG5 [18].
The ISG15/ubiquitin cross-reacting protein (UCRP) gene comprises two exons
and encodes a 17 kDa polypeptide [19, 20]. The immature polypeptide is cleaved at
its carboxy terminus, generating a mature 15 kDa product that terminates with an
LRLRGG motif that is also found in ubiquitin. The tertiary structure of ISG15 also
resembles ubiquitin, despite having only approximately 30% sequence homology
[21, 22]. ISG15 is induced by type I interferon and serves many functions, acting as
an extracellular cytokine and an intracellular protein modifier [23, 24].
HLA-F adjacent transcript 10 (FAT10; also known as ubiquitin D) also bears two
ubiquitin-like domains. HUB1 has only 22% sequence identity with ubiquitin and
possesses an invariant C-terminal double-tyrosine motif, unlike the double glycine
residues present in ubiquitin and other UBLs [25].
3. Ubiquitin modification enzymes
3.1 E1 ubiquitin-activating enzymes (UBA)
E1 UBA enzymes adenylate the C-terminal glycine residue (Gly 76) of ubiquitin
polypeptides, coupling them with ATP. The C-terminal ubiquitin polypeptide gly-
cine residue is linked to AMP via an acyl-phosphate bond, and the adenylated
ubiquitin polypeptide is linked with the sulfhydryl side chain of a cysteine residue
(Cys 632 in human UBA1) in the E1 enzyme catalytic center. A thioester interme-
diate (S-ubiquitinyl-(E1 UAE)-L-Cys) is synthesized in this two-step reaction,
along with AMP and diphosphate (Reaction (1)).
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Ligase
ATPþUbiquitinþ E1 UBA½ ‐L‐cysteine
<¼>AMPþ diphosphateþ S‐ubiquitinyl‐ E1 UBA½ ‐L‐cysteine:
(1)
In human, ten UBA orthologues have been identified that can activate ubiquitin
or UBLs. Ubiquitin-like modifier-activating enzyme 1 (UBA1) is mainly responsible
for ubiquitin-activation and can also activate the NEDD8 UBL peptide [26–28].
UBA2 (or UBLE1B) is also known as SUMO-activating enzyme subunit 2 (SAE2),
and activates the SUMO UBL peptide as heterodimer with SAE1 [29]. UBA3 (or
UBE1C) encodes the NEDD8-activating enzyme E1 catalytic subunit and forms a
heterodimer with NAE1 (or APPBP1, an amyloid-beta precursor protein binding
protein), which activates NEDD8. UBA5 activates UFM1 (ubiquitin-fold modifier
1) [30], while UBA6 (alternatively UBE1L2) is an E1 enzyme involved in UBL
activation [31, 32]. Autophagy related 7 (ATG7) is an E1 enzyme for UBLs including
ATG12 and ATG8. NEDD8-activating enzyme E1 regulatory subunit (NAE1 or
APPBP1) is an E1 enzyme for NEDD8, along with UBA3 [33]. Ubiquitin-like
modifier-activating enzyme 1 Y (UBA1Y) is encoded by the Y chromosome and
expressed specifically during spermatogenesis [34–37]. The UBL, FAT10, is acti-
vated by UBA1 and UBA6. UBA7 is induced by interferon-α and β and involved in
ISG15 induction.
UBA structures consist of an adenylation domain that interacts with ATP and
UBLs, a catalytic domain comprising a Cys residue that binds to UBLs, and a
C-terminal ubiquitin fold domain (UFD) required for binding to E2 enzymes.
In a study of mammalian UBA1 with a temperature-sensitive (ts) mutation, cells
expressing the ts-UBA1 mutant exhibited cell cycle arrest at the G2/M phase transi-
tion, as well as dramatically decreased ubiquitin conjugation [38, 39]. UBA1-
knockdown in human cells also leads to reduced cell proliferation [40]. Further-
more, cells expressing the ts-UBA1 mutant show reduced receptor tyrosine kinase
endocytosis and degradation [41]. In addition, mice lacking UBA3 are characterized
by a mitotic defect in G1/G0 transition, that causes accumulation of SCF ligase
targets, including Cyclin E and β-catenin.
3.2 E2 ubiquitin-conjugating enzymes (UBC)
E2 UBC enzymes transthiolate activated ubiquitin from S-ubiquitinyl-[E1 UBA]
to themselves. A thioester linkage is formed between an E2 UBC and ubiquitin via
the C-terminal glycine of ubiquitin, and the sulfhydryl side chain of a Cys residue in
the E2 UBC catalytic center [42] (Reaction (2)).
S‐ubiquitinyl‐ E1 UBA½ ‐L‐cysteineþ E2 UBC½ ‐L‐cysteine
<¼> E1 UBA½ ‐L‐cysteineþ S‐ubiquitinyl‐ E2 UBC½ ‐L‐cysteine
(2)
The transthiolation reaction involving S-ubiquitinyl-[E1 UBA]-L-cysteine and
E2 UBC is strongly stimulated by occupancy of the nucleotide-binding site by either
adenylated ubiquitin or ATP alone [43]. Ubiquitin transfer to the target protein is
assisted by E3 ubiquitin ligases. Homologous to E6-AP C-terminus (HECT) domain
family E3 ligases transfer ubiquitin to the target via a Cys residue in the E3 ligase. By
contrast, Really Interesting New Gene (RING) family E3 ligases transfer ubiquitin
directly to target proteins. The properties of specific E2 UBC enzymes determine
the ubiquitin moiety and substrate specificity of E3 ligases. Indeed, the specificity of
interactions with E2 reflect E3 substrate specificity. Amino acids surrounding the




ubiquitin-conjugating (UBC) domain or the core catalytic domain [44]. The
UBC domain folds an N-terminal helix (H1), a four-stranded β-meander structure
(S1–S4), a short 310-helix (H2), and three C-terminal helices (H3–H5) [45, 46].
Amino acid sequence variations in the UBC domain contribute to specific interac-
tions with E1 UBAs, E3 ligases, and target proteins [47–51].
E2 UBCs are divided into four classes based on structural differences [52]: class I
E2 enzymes consist of only a UBC domain; class II E2 enzymes contain additional
C-terminal extension residues; class III E2 enzymes have N-terminal extension resi-
dues; and class IV E2s have both N- and C-terminal extensions. Class II UBC2 and
UBC3 proteins have acidic C-terminal extensions, which mediate a preference for
binding to basic substrates, including histones [53–55]. The acidic extension is also
required to contact basic canyon residues of the Cul1 subunit of the SCF RING
subcomplex (ROC1-CUL1) [56–58]. UBC6 processes C-terminal extensions, to
promote ER localization [59, 60]. Class II UBCs include: E2-25K (yeast UBC1)
[61], UBC4 [62], UBCH6, UBCH7 [63], UBE2E1 [64], UBE2E2 [65], and
UBE2E3 [66, 67].
UBL-specific E2 UBC enzymes process proteins for ubiquitin-like modification.
UBC9 is an E2 UBC enzyme specific for the UBL, SUMO, and binds directly to
SUMO substrates through a specific short consensus amino acid motif, Y-K-X-
[D/E], where Y is any bulky hydrophobic amino acid, including isoleucine, leucine,
or valine; K is the lysine residue which is modified by SUMO; X is any residue; D is
aspartic acid; and E is glutamic acid [68]. UBC9 contains N- and C-terminal exten-
sion residues within the UBC domain, and non-conserved residues in the H1 helix
and the insertion β-sheet (S1/2) are required for both interaction with UBA
enzymes and formation of the SUMO-thioester bond [69, 70]. ATG3/AUT1 is a
dedicated E2 UBC for ATG8 [71]. UBC12 is an E2 UBC specific for NEDD8, which
interacts with the NEDD8 E1 UBA via its UBC domain [72, 73], and includes a
unique N-terminal region that docks to the E1 enzyme, UBA3, but not to other
UBAs. The E2 for ISG15, UBCH8, takes part in reactions involving both UBEL1, the
E1 for ISG15, and UBA1, the E1 for ubiquitin [7].
3.3 E3 ubiquitin ligases
E3 ubiquitin ligases are also referred to as ubiquitin-protein ligases, E3 ligases, or
E3 enzymes. Ubiquitin is covalently bonded to the ɛ-amino group of a lysine residue
within the substrate protein via an isopeptide bond. The last step in this binding is
mediated by E3 ubiquitin ligases, which determine the substrate specificity by 
to target proteins. E3 ubiquitin ligases transfer ubiquitin linked with a UBC to the
ϵ-amino group of a lysine residue of the target protein. An isopeptide bond is
formed between the C-terminal glycine residue of ubiquitin and an ϵ-amino group
of a lysine residue in the target protein.
E3 ubiquitin ligases are divided into three major classes: HECT type
(Section 3.3.1), RING-type (Section 3.3.3), and U-box E3 ligases (Section 3.3.4).
HECT type E3 ubiquitin ligases form a thioester intermediate with the active-site
cysteine of the E3, following the formation of an isopeptide bond between the
C-terminal glycine residue of ubiquitin and the ϵ-amino group of a lysine residue in
the target protein. RBR-type E3 ubiquitin ligases (Section 3.3.2) mediate similar
reactions to HECT type E3 ligases. RING-type and U-box E3 ligases mediate
different reactions from HECT and RBR-type E3 ligases, in which ubiquitin is
transferred from ubiquitinyl-UBC directly to the target protein without formation
of a thioester intermediate. Multi-subunit RING-type E3 ligases (Section 3.3.3.1)




3.3.1 HECT-type E3 ubiquitin transferases (EC 2.3.2.26)
HECT-type E3 ligases transfer ubiquitin from an E2 ubiquitin-conjugating
enzyme (EC 2.3.2.23) to a cysteine residue in the HECT domain in the C-terminal
region of an E3 ligase (Reaction (3)). The activated ubiquitin from S-ubiquitinyl-
[E3 ligase]-L-cysteine is transferred from the intermediate to the target protein
(Reaction (4)). The C-terminal glycine residue of the received ubiquitin is linked
with the ε-amino chain of a lysine residue of the acceptor protein, forming an
isopeptide bond. Importantly, the HECT domain forms a thioester intermediate
with ubiquitin, unlike other E3 ligases.
S‐ubiquitinyl‐ E2 UBC½ ‐cysteineþ HECT‐type E3
 
‐cysteine






‐cysteineþ acceptor protein½ ‐lysine
<¼> HECT‐type E3
 
‐cysteineþN6‐ubiquitinyl‐ acceptor protein½ ‐lysine
(4)
S‐ubiquitinyl‐ E2 UBC½ ‐L‐cysteineþ acceptor protein½ ‐L‐lysine
<¼> E2 UBC½ ‐L‐cysteineþN 6ð Þ‐ubiquitinyl‐ acceptor protein½ ‐L‐lysine
(5)
HECT type E3 ligases catalyze a thioester bond between a C-terminal glycine
residue of ubiquitin and themselves and then transfer the ubiquitin to a substrate
protein. HECT type E3 ligase family proteins possess a well-conserved, approxi-
mately 350 residue, catalytic HECT domain close to their C-terminal region [74, 75].
The HECT domain has a bi-lobal structure comprising an approximately 250 residue
N-lobe, required for the binding to UBC-ubiquitin complex, and a C-lobe of around
100 residues, required for ubiquitin transfer [74, 76, 77]. Various linker sequences
between the two HECT domain lobes mediate the properties of HECT type E3
ligases in accepting ubiquitin from E2 enzymes and transferring it to a target
substrate.
The HECT type E3 ligase, E6-AP, can ubiquitinate p53 in the presence of human
papillomavirus E6 protein [75, 78, 79], and another HECT E3 enzyme NEDD4
ubiquitinates SMAD proteins, thereby regulating transcription factors mediating
TGFβ signaling [80], the P63 tumor antigen [81], and MDM2 [82]. HECW1 [83],
HECW2 [84], WWP1 [85], HERC1 [86], HERC2 [87], and ITCH [88] also belong to
the HECT type E3 ubiquitin ligase family.
3.3.2 RBR-type E3 ubiquitin transferase (EC 2.3.2.31)
RBR-type E3 ubiquitin transferases possess two RING finger domains, each of
which is separated by an internal IBR (In Between RING) motif. These E3 ligases
bind to the Cullin-RING ubiquitin Ligase (CRL) complex (see Cullin-type E3 NDD8
transferase), within which a neddylated cullin scaffold protein and a substrate
recognition module are required for ubiquitin transfer. The first RING domain
binds S-ubiquitinyl- [E2 UBC]-cysteine and transfers the ubiquitin to an internal
Cys residue in the second RING domain (Reaction (6)), followed by transfer of the
ubiquitin from the Cys residue in the second RING domain to a Lys in the acceptor
protein (Reaction (7)). RBR-type ligases stimulate a cycling ubiquitination reaction
via the S-ubiquitinyl-[E2 UBC]-cysteine in the first RING domain [88]. RBR-type
ligase activity depends on the neddylation of the cullin protein in the CRL complex.
RBR-type E3 ubiquitin ligases include Parkin, Parc, RNF19, RNF144, RNF216 RFA1




S‐ubiquitinyl‐ E2 UBC½ ‐cysteineþ RBR‐type E3
 
‐cysteine






‐cysteineþ acceptor protein½ ‐lysine
<¼> RBR‐type E3
 
‐cysteineþN6‐ubiquitinyl‐ acceptor protein½ ‐lysine
(7)
S‐ubiquitinyl‐ E2 UBC½ ‐cysteineþ acceptor protein½ ‐lysine
<¼> E2 UBC½ ‐cysteineþN 6ð Þ‐ubiquitinyl‐ acceptor protein½ ‐lysine
(8)
3.3.3 RING-type E3 ubiquitin transferases (EC 2.3.2.27)
RING E3 ubiquitin ligases (also referred to as RING E3 ligases or ubiquitin
transferase RING E3 enzymes) transfer ubiquitin peptides directly from a
ubiquitinyl-E2 UBC enzyme to an acceptor protein. The ε-amino group of a lysine
residue of the target protein forms an isopeptide bond with the C-terminal glycine
residue of ubiquitin (Reaction (9)). Unlike HECT E3 ligases, the RING-E3 domain
does not create a catalytic thioester intermediate with ubiquitin through a Cys
residue.
S‐ubiquitinyl‐ E2 UBC½ ‐L‐lysineþ acceptor protein½ ‐L‐lysine
<¼> E2 UBC½ ‐L‐cysteineþN 6ð Þ‐ubiquitinyl‐ acceptor protein½ ‐L‐lysine
(9)
Human proteome analysis has identified approximately 580 genes encoding
putative RING-type ubiquitin E3 ligase family proteins, which is more than the
number of protein kinase genes (518) [91]. Among RING-type E3 ligase genes, 309
and 270 encode single and multi-subunit RING-type E3 ligase molecules, respec-
tively. While RING-type E3 ubiquitin ligase family proteins do not form thioester
intermediates with ubiquitin, they function as a scaffold for ubiquitin-charged UBC
and the substrate. RING-type E3 ligases contain both a RING domain and a
substrate-binding site, and almost half the RING proteins belong to multisubunit
RING-type E3 ligases, which require an additional subunit for substrate recognition
(see multisubunit RING-type ubiquitin ligases).
The RING domain was initially thought to function as a DNA binding domain
because of the discovery of RING domain-containing proteins with DNA binding
activity [92, 93]. RING-type E3 ligases were subsequently identified as interacting
partners of the human E2 ubiquitin-conjugating enzyme UBCH5 [94], which has
self-ubiquitination activity that depends on its RING domain sequence. The canon-
ical RING domain structure consists of a Zn2+-coordination complex and o series of
Cys and His residues and mediates E2-dependent ubiquitylation. The coordination
complex with two zinc ions forms a cross-brace structure. RING finger domains
have consensus sequences that are classified into two different types, C3HC4-type
(RING-HC) and C3H2C3-type (RING-H2), according to the cysteine/histidine
arrangement (where C = Cys and H = His) [95]. The C3HC5-type RING domain has
different properties from the C3HC4 RING-HC finger [96], Casitas B-lineage Lym-
phoma (c-Cbl), which is a RING-HC type ligase. Ubiquitination activity modulates
receptor tyrosine kinase signaling [97] and structural analysis of the c-Cbl-UbcH7-
substrate tertiary complex showed that the interaction surface of the UbcH7 E2
enzyme is commonly used by both c-Cbl and HECT-type E3 ligases, where c-Cbl
binds UbcH7 using both its RING domain and linker helix structure [50]. The amino
acid residues involved in the interaction are structurally similar between E2
enzymes and E3 ligases.
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BRCA1 forms a heterodimer with the RING-type ligase BARD. The dimerization
of two RING-type E3 ligases results in upregulation of ubiquitination activity. By
biochemical approaches, UbcH5c and UbcH7 enzymes were identified as candidate
E2 enzymes for the BRCA1-BARD complex. Christensen et al. developed an excel-
lent method for identifying E2-E3 pairing [98, 99], using a BRCA1-BARD fusion
protein; BRCA1 can synthesize specific polyubiquitin chain linkages, depending
on the presence of a paired E2 enzyme [98]. This approach has increased the
identification of E2-E3 pairs; for example, RNF213, a RING-HC type E3 ligase and
its paired UBC13E2 enzyme were identified using this method [100]. UBCH5b
mutants, which can bind to E3 ligase, exhibit defective stimulation by E3 ligases
[101]. Ubiquitin-charged E2 is conformationally activated by binding to the
RING domain [101–103]. Furthermore, the interaction between E1 and E2
enzymes can direct substrate specificity, ubiquitin transfer, and polyubiquitin
chain linkages.
Some RING-type ubiquitin ligase family members form hetero- or homo-
multimers through the RING domain or its surrounding region. RING-RING com-
plexes, including MDM2-HMDX, BRCA1-BARD1, and RING1-BMI1, form
heterodimers. In heterodimers, one partner (HDMX, BRAD1, and BMI1) lacks
ubiquitin ligase activity, while the other partner (MDM2, BRCA1, and RING1) has
E2 UBC binding activity. Heterodimer formation leads to stabilization of E2-E3
binding, and in dimerizing E3 ligases, the five C-terminal residues of the RING
domain are essential for both dimer formation and E3 activity [104–106].
TRAF2, cellular inhibitor of apoptosis (cIAP; officially known as BIRC2), SIAH,
BIRC7, and RNF213 form homodimers [100, 107–111]. Dimeric BIRC7 recruits
UBCH5B-ubiquitin and optimizes the donor ubiquitin configuration for transfer
[112]. Homo- and hetero-dimerization of RING-type ubiquitin ligases may stabilize
their interactions with ubiquitin-charged UBC E2 enzymes and optimize ubiquitin
transfer activity.
3.3.3.1 Multisubunit RING protein complexes
Enzymes of the RING-type E3 ubiquitin ligase family do not bind directly to a
substrate, but rather form a complex with a cullin scaffold protein and substrate
recognition modules, referred to as CRL complexes. The SCF complex (SKP, Cullin,
F-box containing complex) and anaphase-promoting complex/cyclosome (APC/C)
(anaphase-promoting complex/cyclosome) are two major multisubunit RING
containing complexes.
Ubiquitination by SCF and APC/C are implicated in the degradation of cell cycle
proteins [113–116]. APC/C regulates mitosis and entry into the G1 phase of the cell
cycle, and SCF controls S phase progression.
SCF E3 complexes comprise at least four different subunits, including the F-box
protein, SKP adaptor protein, Cullin scaffold protein, and Rbx RING-type E3 ligase
[116–119]. The F-box motif is a protein–protein interaction motif comprising
approximately 50 amino acid residues. There is low sequence identity among F-box
proteins, which recognize and bind substrate and bridge connections between
adaptor proteins (including SKP1) and substrates. Phosphorylation of F-box pro-
teins regulates their interactions with substrates. The SKP adaptor proteins, SKP2
(S-phase kinase-associated protein 2), β-TrCP (beta-transducin repeat-containing
protein), FBW7, and FBXO4 are F-box proteins involved in cell-cycle regulation.
Cullins are scaffold proteins for ubiquitin ligases; CUL1 is a subunit of the SCF
complex, and the Cullin-homology domain at its C-terminus interacts with RING
E3 ligases while the N-terminal region can interact with the adaptor protein, SKP2.




complexes. The adaptor proteins SKP1 and CUL1 and the RING-type E3 ligase RBX1
form the CRL catalytic core complex.
APC/C is a multisubunit RING-type E3 ligase containing approximately 13
subunits. The Cullin subunit protein, APC2, and the RING H2 type E3 ligase,
APC11, form the catalytic core domain [120–122]. TPR (tetratricopeptide residue)
motif-containing subunits, including CDC16, CDC27, CDC23, and APC5, are
thought to function as scaffold assembling proteins. Two co-activators, CDC20
(cell division cycle homologue 20) and FZR/CDH1 (Fzy-related/cell division
cycle 20 related 1), bind to the CDC27 subunit of APC/C through their WD40
repeat and determine APC/C substrate specificity dependent on cell cycle to
stages [115, 118, 123–128]. The APC10 subunit contributes to optimal
co-activator-dependent substrate recognition and substrate affinity [129–131].
APC/C-mediated ubiquitination depends on destruction box, KEN box, and CRY
box sequences in the substrate [132–140]. Assembly of these co-activators into the
APC/C complex in G1 or M phase during cell cycle is regulated by phosphorylation
[141–144].
3.3.4 U-Box E3 ubiquitin ligases
The U-box domain displays a similar three-dimensional structure to the RING
domain [145]. The U-box domain shows similarity to UFD2, which has a
multiubiquitin chain elongation activity (known as E4 activity) [146]. Unlike the
RING domain, the U-box domain does not form a coordination complex consisting
of a central zinc ion through Cys residues; rather, the U-box domain structure is
maintained by hydrogen bonding. The U-box domain has ubiquitin ligase activity,
and the U-box protein, carboxyl terminus of HSC70-interacting protein (CHIP),
also has E4 activity and includes tetratricopeptide repeat and U-box domains. The
C-terminal U-box domain interacts with the molecular chaperones HSC70, HSP70,
and HSP90 [147], in the presence of unfolded or misfolded proteins, where CHIP
regulates protein quality control [148, 149].
U-box proteins have various structures; for example, ARC1, CMPG1, PUB13,
and PUB20 contain armadillo which represents approximately 40 amino acids
tandem repeats sequence. PUB23 has a serine/threonine kinase domain while
PUB59 and PUB60 have WD40 repeats. These domains may coordinate the
function of ubiquitin ligase activity by the U-box domain.
4. Conclusions
Research conducted over several decades has uncovered the cellular and bio-
chemical functions involved in ubiquitin modification. Protein–protein networks
and studies of complex structures have contributed to unraveling the biochemical
mechanisms underlying ubiquitin modification. Identification of physiological E2
UBC-E3 ligase pairings has facilitated understanding of modification-types and
associations. Deep understanding of the structures and biochemical processes
involved in ubiquitin modification has contributed to determination of E3 ligase-
substrate pairing and network construction. RING-type ubiquitin ligases comprise
the largest gene family and are associated with various cellular processes and several
diseases. Fundamental questions remain to be answered regarding the biological
functions served by ubiquitin modification. Extensive further study of enzymes
involved in ubiquitination and related processes has potential to contribute to the
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